HC Wainwright & Co. Maintains Buy on Verona Pharma, Raises Price Target to $90

Benzinga · 06/02 11:07
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $85 to $90.